{"id":129689,"title":"Ananda Pharma plans exit from AQSE as it pivots to private structure","publisher":"Share Talk","author":"sharetalk","published":"2025-11-26T07:52:49+00:00","modified":"2025-11-26T07:52:49+00:00","canonical_url":"https://www.share-talk.com/ananda-pharma-plans-exit-from-aqse-as-it-pivots-to-private-structure/","markdown_url":"https://www.share-talk.com/ananda-pharma-plans-exit-from-aqse-as-it-pivots-to-private-structure.md","json_url":"https://www.share-talk.com/ananda-pharma-plans-exit-from-aqse-as-it-pivots-to-private-structure.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["ANA","Ananda Developments","Aquis Stock Exchange Growth","CBD","Drug","Great Ormond Street Hospital.","Melissa Sturgess","University College London","University of Edinburgh"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/03/health-care.webp?fit=1200%2C800&quality=80&ssl=1","format":"news","language":"en-GB","content":"[Ananda Pharma PLC](https://www.investegate.co.uk/announcement/rns/ananda-pharma-plc--ana/posting-of-q-a/9257308) has announced plans to [withdraw its shares](https://www.share-talk.com/ananda-pharma-to-delist-from-aqse-and-go-private-to-refocus-on-drug-development/)** from the AQSE Growth Market and re-register as a private company**, proposing to continue operations under the name **Ananda Pharma Limited**.\n\nThe UK-based biopharmaceutical group has published a detailed shareholder circular alongside a **Q&A document on its website**, designed to clarify the rationale and implications of the move. Shareholders are being asked to vote on the proposals, which are positioned as part of a strategic shift to reduce regulatory costs and improve operational focus.\n\nAnanda says the transition will allow greater flexibility and enable more efficient allocation of capital towards its core mission: the development of **regulatory-approved cannabidiol (CBD) medicines** targeting complex chronic conditions, including **endometriosis and chemotherapy-induced pain**.\n\nThe Company has received a number of questions from shareholders about the proposals to be considered at the General Meeting. Those questions and the answers from management can be found on the company’s website here: [https://investors.anandapharma.co.uk/activity-updates/PGNgYr-questions-in-relation-to-the-companys-recent-announcement-about-its-proposed-withdrawal-from-the-aqse-growth-market](https://investors.anandapharma.co.uk/activity-updates/PGNgYr-questions-in-relation-to-the-companys-recent-announcement-about-its-proposed-withdrawal-from-the-aqse-growth-market)\n\nThe company believes operating as a private entity will better support long-term clinical progress and funding strategy, while maintaining transparency and engagement with its shareholder base.\n\nTo stay up to date with Ananda’s news please follow our social media channels:  \n\n·              Investor Hub: [https://investors.anandapharma.co.uk/s/ea8f93](https://investors.anandapharma.co.uk/s/ea8f93)\n\n·              Instagram: [https://www.instagram.com/anandapharmaplc/](https://www.instagram.com/anandapharmaplc/)\n\n·              LinkedIn[:](https://www.linkedin.com/company/anadevelopments/)  [https://www.linkedin.com/company/anandapharma](https://www.linkedin.com/company/anandapharma)\n\n·              X[:](https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA) [https://twitter.com/AnandaPlc](https://twitter.com/AnandaPlc)"}